Whitehawk Therapeutics Inc
WHWK
NASDAQ
Biotechnology
$4.46
USD
-0.22 (-4.70%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $253.32M
Volume 260.3K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-79.83M
TTM
— YoY
Operating Cash Flow
$-69.35M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | -100.0% | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.9 | 5.2 | 5.9 | 6.3 | 5.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 54.7 | 19.5 | 24.9 | 23.5 | 18.1 |
Operating Income | -54.7 | -19.5 | -24.9 | -23.5 | -18.1 |
EBITDA | -54.7 | -19.5 | -24.9 | -23.5 | -18.1 |
Other Income / Expense | 0.2 | -0.1 | 0.0 | 0.0 | -0.0 |
Total Other Income / Expense | 2.1 | 1.8 | 1.6 | 1.3 | 1.5 |
Income Before Income Taxes | -52.6 | -17.7 | -23.3 | -22.2 | -16.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -52.6 | -17.7 | -23.3 | -22.2 | -16.6 |
Consolidated Net Income / Loss | -52.6 | -17.7 | -23.3 | -22.2 | -16.6 |
Net Income Attributable to Common Shareholders | -52.6 | -17.6 | -23.4 | -22.2 | -16.6 |
Basic EPS | -$0.76 | -$0.26 | -$0.34 | -$0.32 | -$0.20 |
Diluted EPS | -$0.76 | -$0.26 | -$0.34 | -$0.32 | -$0.20 |
Basic Shares Outstanding | 69.1M | 69.2M | 69.6M | 69.2M | 82.9M |
Diluted Shares Outstanding | 69.1M | 69.2M | 69.3M | 69.2M | 82.9M |